Allogene Therapeutics (NASDAQ:ALLO) EVP Zachary Roberts Sells 26,269 Shares

Allogene Therapeutics, Inc. (NASDAQ:ALLO) EVP Zachary Roberts sold 26,269 shares of Allogene Therapeutics stock in a transaction that occurred on Wednesday, January 21st. The shares were sold at an average price of $1.56, for a total transaction of $40,979.64. Following the transaction, the executive vice president directly owned 616,866 shares in the company, valued at approximately $962,310.96. This trade represents a 4.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Allogene Therapeutics Stock Performance

Shares of ALLO remained flat at $1.72 during mid-day trading on Friday. 7,529,018 shares of the stock were exchanged, compared to its average volume of 5,383,801. Allogene Therapeutics, Inc. has a 12 month low of $0.86 and a 12 month high of $3.78. The stock has a market cap of $386.54 million, a price-to-earnings ratio of -1.76 and a beta of 0.51. The firm has a 50-day moving average of $1.45 and a two-hundred day moving average of $1.29.

Allogene Therapeutics (NASDAQ:ALLO) last released its earnings results on Thursday, November 6th. The company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.04. As a group, research analysts predict that Allogene Therapeutics, Inc. will post -1.28 earnings per share for the current year.

Wall Street Analyst Weigh In

ALLO has been the topic of a number of recent analyst reports. Citigroup upgraded shares of Allogene Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Friday, January 9th. JPMorgan Chase & Co. restated an “underweight” rating on shares of Allogene Therapeutics in a report on Friday, October 10th. Citizens Jmp upgraded shares of Allogene Therapeutics from a “market perform” rating to an “outperform” rating and set a $5.00 price target for the company in a research report on Friday, January 9th. Weiss Ratings restated a “sell (e+)” rating on shares of Allogene Therapeutics in a report on Wednesday, October 8th. Finally, Wall Street Zen upgraded Allogene Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, November 28th. Ten investment analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $8.40.

Institutional Trading of Allogene Therapeutics

Several large investors have recently made changes to their positions in the business. Savant Capital LLC bought a new stake in shares of Allogene Therapeutics during the third quarter valued at approximately $27,000. Russell Investments Group Ltd. lifted its position in Allogene Therapeutics by 11,159.8% in the 3rd quarter. Russell Investments Group Ltd. now owns 21,844 shares of the company’s stock valued at $27,000 after acquiring an additional 21,650 shares in the last quarter. Caitong International Asset Management Co. Ltd raised its position in Allogene Therapeutics by 5,267.6% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 24,047 shares of the company’s stock valued at $30,000 after buying an additional 23,599 shares during the last quarter. Mercer Global Advisors Inc. ADV acquired a new stake in Allogene Therapeutics in the 3rd quarter valued at $30,000. Finally, Brighton Jones LLC boosted its stake in shares of Allogene Therapeutics by 81.6% during the 3rd quarter. Brighton Jones LLC now owns 25,168 shares of the company’s stock worth $31,000 after buying an additional 11,311 shares during the last quarter. Institutional investors own 83.63% of the company’s stock.

Allogene Therapeutics Company Profile

Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic, or “off-the-shelf,” chimeric antigen receptor T-cell (CAR T) therapies to treat a range of hematologic malignancies and solid tumors. The company leverages gene-editing technologies to generate universally compatible engineered T cells, aiming to overcome the limitations of patient-specific CAR T approaches such as manufacturing delays, variable product quality and treatment resistance.

The company’s pipeline includes multiple allogeneic CAR T candidates targeting key antigens in blood cancers.